Patent · US Active

Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection

US10071108B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITE CLAUDE BERNAD LYON 1 · FR
ENS—ECOLE NORMALE SUPÉRIEURE DE LYON · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
EDELRIS · FR
POXEL · FR

Inventors

Patrice Andre · Saint-Jean-de-Braye, FR
Vincent Lotteau · Val-de-Reuil, FR
Pauline Radreau · Val-de-Reuil, FR
Marine Gilardone · Millery, FR
Amaury Patin · Lausanne, CH
Didier Roche · Écully, FR
Daniel Cravo · Sartrouville, FR
Sophie Hallakou-Bozec · Montrouge, FR

Key dates

Filing date	Feb 19, 2018
Grant date	Sep 11, 2018
Priority date	—
Expiry date	Feb 19, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.